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Use of Plasma Renin Activity to Monitor Mineralocorticoid
Treatment in Dogs with Primary Hypoadrenocorticism:
Desoxycorticosterone Versus Fludrocortisone
M.E. Baumstark, J. Nussberger, F.S. Boretti, M.W. Baumstark, B. Riond, C.E. Reusch, and
N.S. Sieber-Ruckstuhl
Background: Measurement of plasma renin activity (PRA) is the gold standard for monitoring mineralocorticoid treat-
ment in humans with primary hypoadrenocorticism (PH).
Objectives: To compare PRA in dogs with newly diagnosed PH, dogs with diseases mimicking PH, and healthy dogs,
and evaluate measurement of PRA to monitor therapeutic eﬀects in dogs with PH treated with diﬀerent mineralocortic-
oids.
Animals: Eleven dogs with newly diagnosed PH (group 1), 10 dogs with diseases mimicking PH (group 2), 21 healthy
dogs (group 3), 17 dogs with treated PH (group 4).
Methods: In group 1, PRA was measured before treatment and at diﬀerent times after initiating treatment. In groups 2
and 3, PRA was measured at initial presentation only. In group 4, no baseline PRA was obtained but PRA was measured
once or every 1–6 months during treatment. Mineralocorticoid treatment consisted of ﬂudrocortisone acetate (FC) or des-
oxycorticosterone pivalate (DOCP).
Results: Plasma renin activity before treatment was increased in dogs with PH compared to normal dogs and dogs with
diseases mimicking PH with median activity of 27, 0.8, and 1.0 ng/mL/h, respectively. In dogs with PH, PRA decreased
and normalized with mineralocorticoid treatment using DOCP but not with FC. In dogs treated with DOCP, PRA was
lower than in dogs treated with FC. Plasma sodium concentrations were higher and potassium concentrations were lower
with DOCP treatment compared to FC treatment.
Conclusion and Clinical Importance: Plasma renin activity is a reliable tool for monitoring mineralocorticoid treatment.
DOCP treatment more eﬀectively suppresses PRA compared to FC in dogs with PH.
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Most dogs with primary hypoadrenocorticism(PH) suﬀer from immune-mediated destruction
of the adrenal cortex, which results in absolute gluco-
corticoid and mineralocorticoid deﬁciency. Because of
negative feedback, high concentrations of endogenous
ACTH accompany glucocorticoid deﬁciency. Similarly,
lack of aldosterone in patients with PH is accompanied
by high concentrations of plasma angiotensin II that
can be estimated indirectly by species-speciﬁc renin
concentrations or by plasma renin activity (PRA) (ie,
angiotensin generated by a plasma sample during
timed incubation).1
Treatment for PH consists of lifelong hormone
replacement.2 Mineralocorticoids usually are replaced
by either ﬂudrocortisone acetate (FC) or desoxycorti-
costerone pivalate (DOCP). Fludrocortisone acetate
administered PO is the most commonly used treatment
for humans with PH and has been recommended for
dogs with PH for many years.3 Fludrocortisone pos-
sesses potent mineralocorticoid activity and some glu-
cocorticoid activity. Thus, in some cases there is no
need for additional glucocorticoid supplementation.
Signs of glucocorticoid overdosage can, however,
occur, even when serum electrolyte concentrations still
are not well controlled.4
Desoxycorticosterone pivalate is a parenterally
administered long-acting mineralocorticoid alternative.
DOCP has no glucocorticoid activity, and additional
supplementation with glucocorticoids is recommended
in all cases. The choice of mineralocorticoid replace-
ment is based on several factors such as product avail-
ability, cost of treatment, and personal preference of
the clinician and client.3,5 Reports on the eﬀectiveness
and monitoring of mineralocorticoid treatment in dogs
with PH are limited. Several authors report that
DOCP is superior to FC, whereas in 1 large compara-
tive clinical study no diﬀerence was seen with regard
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to survival time and control of serum electrolyte con-
centrations.3–6 The most important causes of poor
response to treatment in dogs with PH are an inade-
quate mineralocorticoid dose or serious adverse gluco-
corticoid eﬀects. Furthermore, the expense of
mineralocorticoid supplementation may cause some
owners to consider euthanasia.7 In human medicine,
standard monitoring of patients with PH consists of
measurement of serum electrolyte concentrations,
blood pressure, and PRA. PRA determination to con-
trol mineralocorticoid treatment was ﬁrst described in
1975 and had been accepted as the gold standard since
1992.8–11 PRA before treatment is increased in humans
with PH and it decreases during treatment and corre-
lates inversely with mineralocorticoid dose. Therefore,
a target range for PRA is deﬁned for optimal treat-
ment in humans.10
In dogs with newly diagnosed PH, PRA is signiﬁ-
cantly higher than that in normal dogs.1 The role of
PRA in monitoring mineralocorticoid treatment in
dogs with PH has not been investigated. Mineralocor-
ticoid treatment currently is monitored mainly by
serum potassium and sodium concentrations. The
objectives of our study were, ﬁrst, to measure and
compare PRA in newly diagnosed PH dogs, in dogs
with diseases mimicking PH, and in healthy dogs and,
second, to evaluate PRA in dogs with PH during min-
eralocorticoid treatment. We hypothesized that PRA
in dogs with PH would be signiﬁcantly higher than
that in dogs with diseases mimicking PH or in healthy
dogs, that PRA would decrease during mineralocorti-
coid treatment and that it would be lower in well-con-
trolled dogs than in poorly controlled dogs.
Material and Methods
Animals
Group 1: Eleven client-owned dogs with newly diagnosed PH
were prospectively enrolled between January 2011 and August
2013. One of these dogs had been part of a previous study.12
Diagnostic evaluation included CBC, serum biochemical proﬁle,
urinalysis, ACTH stimulation test, measurement of endogenous
plasma ACTH concentration, and abdominal ultrasonography
(with particular attention to the adrenal glands) in all dogs. PH
was conﬁrmed if serum cortisol concentrations after synthetic
ACTH administration did not increase adequately (<1 lg/dL)
and if endogenous baseline plasma ACTH concentrations were
increased (cACTH > 130 pmol/L). Dogs were enrolled in the
study if their serum sodium concentration was <152 mmol/L,
their serum potassium concentration was >5.3 mmol/L, or both.
Dogs with normal electrolyte concentrations and dogs with iatro-
genic PH (ie, previous corticosteroid or trilostane treatment) were
excluded from the study.
Group 2: Ten dogs with diseases mimicking PH diagnosed
between June 2010 and February 2012 were prospectively
enrolled in the study. All dogs initially had been suspected of
having PH but ﬁnally were determined to have a diﬀerent dis-
ease; all had post-ACTH serum cortisol concentrations ≥4.5 lg/
dL. Diseases mimicking PH were associated with clinical signs,
laboratory ﬁndings, or both routinely seen in dogs with PH, such
as vomiting, diarrhea, weakness, lethargy, hyperkalemia, hypo-
natremia, or some combination of these.
Group 3: Twenty-one privately owned dogs were used as con-
trols. The dogs were considered to be healthy on the basis of nor-
mal history and physical examination, as well as unremarkable
hematology and serum biochemistry proﬁle results.
Group 4: Seventeen client-owned dogs with PH that had
already been treated for PH were prospectively enrolled between
June 2010 and July 2013. PH had been diagnosed between
2 weeks and 7 years previously based on typical electrolyte
abnormalities and an inadequate post-ACTH serum cortisol con-
centration (<1 lg/dL). All of these dogs were being treated with
mineralocorticoid and glucocorticoid supplementation at the time
of inclusion into the study.
All procedures were approved by the Cantonal Veterinary
Oﬃce of Zurich (permission number, TVB 72/2011) and con-
ducted in accordance with guidelines established by the Animal
Welfare Act of Switzerland. In addition, informed consent was
obtained from the owners of the healthy dogs.
Analytical Procedures
For the ACTH simulation test, blood samples were collected
before and 60 minutes after IV injection of 250 lg synthetic
ACTH.a Cortisol concentrations were measured by chemilumi-
nescence assay.b The sensitivity of the cortisol assay was 0.2 lg/
dL. Endogenous plasma ACTH concentration before ACTH
stimulation was determined by a chemiluminescence assay.b
Blood for cACTH determination was collected into chilled
EDTA-coated tubes placed on ice and centrifuged at 4°C. Corti-
sol and cACTH measurements were performed in-house twice a
week; plasma was stored either at 20°C (cortisol) or at 80°C
(ACTH) until assayed.
Plasma renin activity was measured with an enzymatic assay
in the Division of Angiology and Hypertension, Department of
Medicine, Lausanne University Hospital, Lausanne, Switzer-
land. The method is based on trapping of angiotensin I gener-
ated in plasma during incubation at 37°C and subsequent
radioimmunoassay.13 The detection limit was 0.025 ng AngI/
mL/h. The within- and between-assay precisions were charac-
terized by coeﬃcients of variation of 5.1 and 13.0%, respec-
tively. The reference values (5 and 95% percentiles) for healthy
dogs were 0.1–1.7 ng AngI/mL/h and were virtually identical
to human normal values (0.05–2.4 ng AngI/mL/h) and they
were (unlike in human subjects) independent of the postpran-
dial time.14 Blood was collected into chilled EDTA-coated
tubes, placed on ice and centrifuged immediately at 4°C.
Plasma samples were batched and stored at 80°C before
analysis.
Study Design
In dogs with newly diagnosed PH (group 1, n = 11), PRA was
measured before treatment. Subsequently, in 8 of these dogs, fol-
low-up PRA measurements were obtained at diﬀerent time points
during hormone replacement treatment (n = 37). The results in
these 8 dogs later were included in the calculations for Figures 3,
4.
In dogs with diseases mimicking PH (group 2, n = 10), PRA
was measured once at initial presentation.
In healthy dogs (group 3, n = 21), PRA was measured before
and 2 hours after feeding.
In dogs with previously diagnosed PH and included in the
study during ongoing hormone replacement treatment (group 4,
n = 17), PRA was measured once (5 dogs) or repeatedly at 1- to
6-month interval (12 dogs) for a total of 72 plasma samples. The
results in these 17 dogs later were included in the calculations for
Figures 3, 4.
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Treatments
Mineralocorticoid replacement treatment of conﬁrmed PH
consisted of ﬂudrocortisone acetate (FC) or DOCP. The starting
dosage of ﬂudrocortisone acetatec was 0.01–0.02 mg/kg/d PO
divided twice daily. Eﬃcacy of FC treatment was assessed regu-
larly by monitoring clinical signs, renal function (BUN and
serum creatinine concentration) and serum electrolyte concentra-
tions (sodium, potassium, phosphorus). The FC dosage was
adjusted mainly according to the serum potassium concentration.
Dose adjustments were made in increments of 0.025–0.1 mg/dog
depending on the size of the dog. The starting dosage and start-
ing injection interval of DOCPd was 2 mg/kg SC q25 days.
Depending on electrolyte concentrations 14 days after injection,
the DOCP dosage was adjusted. In the event of normal serum
electrolyte concentrations, the DOCP dose was slightly decreased
(5–10%) at the next injection. In the case of normal serum elec-
trolyte concentrations at the time of the next injection, the injec-
tion interval was increased stepwise by 1 day.
Seven of the dogs with newly diagnosed PH were started on FC
treatment and 4 of them on DOCP treatment. Two of the dogs
started on FC treatment were later changed to DOCP treatment.
Fifteen of the dogs with previously treated PH were on FC
treatment and 2 on DOCP treatment at the time of their inclu-
sion in the study. Three dogs treated with FC later were changed
to DOCP treatment.
All dogs also were treated with glucocorticoids. The following
standardized protocol was used for guiding glucocorticoid treat-
ment: starting dosage of 2 mg/kg prednisolone IV after the
ACTH stimulation test; then, 1 mg/kg prednisolone IV q6h dur-
ing the ﬁrst 24 hours. If the dogs seemed stable after 24 hours,
the glucocorticoid dosage was decreased to 0.5 mg/kg predniso-
lone IV q12h. Prednisolone treatment was changed to PO as
soon as the dogs ate and vomiting had stopped. At the time of
discharge, the prednisolone dosage was decreased to 0.5 mg/kg
PO q24h. Additional glucocorticoid reduction was individualized
based on clinical signs (eg, appetite, activity level, diarrhea, vom-
iting, polyuria, polydipsia, weight gain) and on the assessment of
the clinician. In general, the goal was to reach a glucocorticoid
dosage of no more than 0.1–0.2 mg/kg PO q24h. In dogs with
signs of glucocorticoid over dosage (eg, polyuria, polydipsia,
weight gain), glucocorticoid treatment was decreased further and
in dogs treated with FC stopped if possible.
Statistical Analysis
Statistical analysis was performed with commercial software by
using nonparametric tests.e,f Data are expressed as median and
range. Diﬀerences in PRA before or after feeding were tested by
using the Wilcoxon signed rank test. Diﬀerences in PRA among
groups were tested by using the Kruskal-Wallis H-test and Dunn’s
posttest. Changes in PRA during treatment were tested by Fried-
man’s repeated measures test and Dunn’s posttest. Diﬀerences in
PRA as well as in sodium and potassium concentrations between
dogs on FC and DOCP treatment were tested by the Mann-Whit-
ney test. For dogs with repeated measurements, mean PRA, and
serum sodium and potassium concentrations during FC or DOCP
treatment were determined and analyzed statistically. Diﬀerences
in the numbers of dogs with normal or abnormal electrolyte con-
centrations between the 2 treatment groups were tested by the
Fisher’s exact test. Linear correlation between PRA and serum
sodium and potassium concentrations was calculated by Spear-
man nonparametric correlation. As above, for dogs with repeated
measurements, mean PRA, and serum sodium and potassium
concentrations during FC or DOCP treatment were analyzed. The
level of signiﬁcance was set at P < .05.
Results
Animals
Group 1: in the dogs with newly diagnosed PH, the
age range was 1–10 years (median, 5 years) and the
body weight ranged from 1.9 to 28.8 kg (median,
8.5 kg). There were 5 males (2 castrated) and 6 females
(5 spayed). Nine purebred dogs and 2 mixed-breed
dogs were included. No breed was overrepresented.
Group 2: in the dogs with diseases mimicking PH,
the age range was 1–13 years (median, 3.5 years) and
the body weight ranged from 6.7 to 42 kg (median,
19.9 kg). There were 5 males (3 castrated) and 5
females (3 spayed). Eight purebred dogs and 2 mixed-
breed dogs were included. The ﬁnal diagnoses were
acute gastroenteritis (2), food-responsive enteropathy
(2), inﬂammatory bowel disease (1), gastric ulceration
(1), idiopathic megaesophagus (1), hypothyroidism (1),
primary hyperparathyroidism (1) diroﬁlariasis, and
leishmaniasis (1).
Group 3: in the healthy dogs, the age range was 1–
12 years (median, 4 years) and the body weight ranged
from 5 to 35 kg (median, 22 kg). There were 8 males
(2 castrated) and 13 females (11 spayed). Sixteen pure-
bred dogs and 5 mixed-breed dogs were included.
Group 4: in the dogs with already treated PH, the age
range was 1–14 years (median, 8 years) and the body
weight ranged from 3.6 to 34 kg (median, 10.6 kg).
There were 7 males (4 castrated) and 10 females (9
spayed). Eleven purebred dogs and 6 mixed-breed dogs
were included. No breed was overrepresented.
PRA in Healthy Dogs
There was no inﬂuence of feeding on PRA in healthy
dogs (P = .44). Fasted PRA in healthy dogs ranged
from 0.1 to 1.3 ng/mL/h (median, 0.6 ng/mL/h) and
postprandial PRA ranged from 0.1 to 1.7 ng/mL/h
(median, 0.75 ng/mL/h). The 5 and 95% percentiles of
fasted PRA were 0.1 and 1.3 and those of postprandial
PRA were 0.1 and 1.7 ng/mL/h, respectively.
Comparison of PRA in Dogs with Newly Diagnosed
PH, Dogs with Diseases Mimicking PH, and
Healthy Dogs
Plasma renin activity before treatment was signiﬁ-
cantly higher in dogs with PH (2.9–89 ng/mL/h; med-
ian, 27 ng/mL/h) than in dogs with diseases mimicking
PH (0.5–2.8 ng/mL/h; median, 1.0 ng/mL/h; P < .001)
and in healthy dogs (0.1–1.7 ng/mL/h; median, 0.8 ng/
mL/h; P < .0001; Fig 1). PRA did not diﬀer signiﬁ-
cantly between dogs with diseases mimicking PH and
healthy dogs (P = .13).
PRA in Dogs with PH Before and After Initiation of
Mineralocorticoid Treatment
Plasma renin activity decreased signiﬁcantly after
the start of mineralocorticoid treatment (P = .04;
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Fig 2A). However, the PRA response was diﬀerent for
the 2 treatments: PRA of dogs treated with FC
remained very high and was unchanged. In contrast, in
dogs treated with DOCP, PRA decreased into the ref-
erence range and even lower during treatment
(Fig 2B). Comparison of the treatment groups at each
follow-up evaluation was not possible because of the
low numbers of dogs.
PRA and Correlation with Serum Sodium or
Potassium Concentrations
There was a signiﬁcant, negative correlation of PRA
and sodium concentrations (r = 0.74, P < .0001) and
a signiﬁcant positive correlation of PRA and potas-
sium concentrations (r = .71, P < .0001) in dogs with
PH (groups 1 and 4) before and during treatment.
PRA and Serum Electrolyte Concentrations in Dogs
with PH Already Treated for PH
For these calculations, 8 dogs from group 1 (4 on
FC and 4 on DOCP treatment) and 17 dogs from
group 4 (15 on FC and 2 on DOCP treatment) were
used. In 2 dogs of group 1 and in 3 dogs of group 4,
mineralocorticoid treatment was changed from FC to
DOCP during the study, leading to 2 and 3 additional
results in the DOCP group. Therefore, a total of 19
results (4 from group 1 and 15 from group 4) in the
FC group and 11 results (6 from group 1 and 5 from
group 4) in the DOCP group were included.
Plasma renin activity was signiﬁcantly lower in dogs
on DOCP treatment (0.04–6.13 ng/mL/h; median,
0.04 ng/mL/h) than in dogs on FC treatment (8.7–
47.5 ng/mL/h; median, 16.8 ng/mL/h; P < .0001;
Fig 3).
Serum sodium concentrations of dogs treated with
DOCP were signiﬁcantly higher (154–158 mmol/L;
median, 156 mmol/L) than those of dogs treated with
FC (138–155 mmol/L; median, 147 mmol/L; P < .0001;
Fig 4A). Serum potassium concentrations of dogs trea-
ted with DOCP were signiﬁcantly lower (4.3–5.1 mmol/
L; median, 4.6 mmol/L) than those of dogs treated with































Fig 1. Plasma renin activity (PRA) of dogs with primary hypo-
adrenocorticism (PH, n = 11), dogs with diseases mimicking PH
(n = 10), and healthy dogs (n = 21). The horizontal bars repre-
sent the medians of each group.
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Fig 2. (A) Plasma renin activity (PRA) of dogs with primary
hypoadrenocorticism (PH) treated with ﬂudrocortisone acetate
(FC, open circles) or with desoxycorticosterone pivalate (DOCP,
closed circles). Three dogs were lost to follow-up (triangles). (B)
Bar graphs showing mean (SD) PRA of dogs with PH treated
with FC (white bars) and DOCP (black bars).























Fig 3. Plasma renin activity (PRA) of dogs with primary hypo-
adrenocorticism on ﬂudrocortisone acetate treatment (FC,
n = 19) and on desoxycorticosterone pivalate treatment (DOCP,
n = 11). The horizontal bars represent the medians.
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Signiﬁcantly more dogs treated with DOCP had
serum sodium (P < .0001) or potassium (P < .0001)
concentrations within the reference range than did
dogs treated with FC.
Change in Mineralocorticoid Treatment
Five dogs were changed from FC to DOCP treat-
ment because of adverse glucocorticoid eﬀects, lack of
normalization of serum electrolyte concentrations, or
both. The FC dosage and the prednisolone dosage at
the time of treatment change ranged from 0.013 to
0.026 mg/kg/d (median, 0.017 mg/kg/d) divided q12h
and from 0 to 0.2 mg/kg/d (median, 0.06 mg/kg/d),
respectively.
In 4 of the dogs, follow-up samples on either FC or
DOCP treatment could be obtained. The PRA and
serum sodium and potassium concentrations in the 4
dogs on FC ranged from 2.8 to 37 ng/mL/h (median,
17 ng/mL/h), 135 to 156 mmol/L (median, 146 mmol/
L), and 4.2 to 7.1 mmol/L (median, 5.6 mmol/L),
respectively. After changing to DOCP treatment, PRA
and serum sodium and potassium concentrations in the
4 dogs ranged from 0.03 to 2.2 ng/mL/h (median,
0.12 ng/mL/h), 151 to 160 mmol/L (median, 156 mmol/
L), and 4.2 to 5.3 mmol/L (median, 4.6 mmol/L),
respectively (Fig 5A–C).
Discussion
Dogs with PH have higher PRA than do healthy
dogs. These results conﬁrm previous observations.1
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Fig 4. Serum sodium (A) and potassium (B) concentrations of
dogs with primary hypoadrenocorticism on ﬂudrocortisone ace-
tate treatment (FC, n = 19) and on desoxycorticosterone pivalate
treatment (DOCP, n = 11). The horizontal bars represent the
medians.
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Fig 5. Eﬀects of switching hormone replacement treatment in 4
dogs with primary hypoadrenocorticism (square, triangle, rhom-
bus, and circle) from ﬂudrocortisone acetate (FC, open symbols)
to desoxycorticosterone pivalate (DOCP, closed symbols). Plasma
renin activity (A), serum sodium concentrations (B), and serum
potassium concentrations (C): All normalize after switching from
initial FC to ﬁnal DOCP treatment. The dotted lines in ﬁgures A
and C represent the upper limit of normal values. The dotted line
in ﬁgure B represents the lower limit of normal values.
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Renal renin secretion apparently is enhanced in an
attempt to try and further stimulate adrenal mineralo-
corticoid secretion, which is lacking in PH. In contrast,
PRA was not increased in dogs with diseases mimick-
ing PH. Dogs with diseases mimicking PH were
included because of clinical signs or laboratory ﬁnd-
ings commonly seen in dogs with PH (eg, gastrointesti-
nal illness, hyponatremia, hyperkalemia). Many of
these dogs presented with decreased plasma volume
(eg, signs of dehydration, low blood pressure, or both)
and were classiﬁed as being critically ill. Thus, they
would have been expected to have high PRA. Possibly,
in contrast to true PH, ﬂuid therapy at the time of
PRA sampling may already have corrected factors (eg,
volume depletion) that would have stimulated renin
secretion in dogs with diseases mimicking PH. Alterna-
tively, hepatic or renal insuﬃciency may have pre-
vented an increase in PRA.
Plasma renin activity in dogs with PH decreased
during mineralocorticoid treatment. This observation
is similar to the situation in humans with PH, in
whom PRA is increased before treatment and
decreases during treatment.10 In human medicine,
PRA is the most sensitive marker for identifying insuf-
ﬁcient or excessive mineralocorticoid replacement
treatment.10 For optimal treatment control of PH,
PRA should be within the reference range of healthy
humans.10 Our results conﬁrm that, in dogs, reference
PRA results are very similar to those of humans when
individuals with or without PH are compared.1,10,13 In
addition, PRA of healthy dogs and dogs with PH on
successful treatment were very similar to those results
in healthy humans.1,10,13 We therefore hypothesize that
PRA can be used to titrate mineralocorticoid treat-
ment in dogs as well as in humans. Interestingly, based
on our PRA results, SC DOCP treatment seemed to
be more eﬀective than PO FC treatment. This observa-
tion was conﬁrmed by serum sodium and potassium
concentrations and also by clinical observations (data
not shown). More dogs treated with DOCP had nor-
mal serum sodium and potassium serum concentra-
tions when compared to dogs treated with FC. PRA
of dogs treated with FC was higher than PRA of dogs
treated with DOCP. Moreover, in the dogs that were
changed from FC to DOCP treatment, pathologically
increased PRA and serum potassium concentrations
and pathologically decreased serum sodium concentra-
tions observed during FC treatment were normalized
after changing to DOCP treatment. Our ﬁndings sug-
gest that DOCP lowers PRA and normalizes serum
electrolyte concentrations in a more predictable way
than does FC. Possible explanations for a lesser eﬀect
of FC treatment in dogs could be decreased absorption
of FC from the gastrointestinal tract, lower mineralo-
corticoid activity of FC compared to DOCP, or
decreased owner compliance with PO administered
medication. Certainly, owner compliance could have
inﬂuenced treatment control in some dogs on FC.
However, owners of dogs with PH understood that
they were treating with a life-threatening disease in
their dogs, and thus poor owner compliance seems an
unlikely explanation. In humans, the mineralocorticoid
replacement treatment of choice in patients with PH is
PO FC. Normalization of serum sodium and potas-
sium concentrations and of PRA seems very consistent
during treatment.10 It is evident however that serum
sodium and potassium concentrations require a smaller
FC dosage for normalization than does PRA.10 The
FC dosage leading to PRA in the desired range shows
considerable interindividual variability.10,15 The pri-
mary problem of FC treatment in dogs is the risk of
adverse glucocorticoid eﬀects. In some dogs, adverse
glucocorticoid eﬀects seem to occur before an FC dos-
age adequate for normalization of serum electrolyte
concentrations and PRA can be achieved. Possibly,
dogs are more sensitive to adverse glucocorticoid
eﬀects or FC may have higher glucocorticoid activity
or lower mineralocorticoid activity in dogs than in
humans.
In the only larger study3 comparing FC and DOCP
treatment in dogs, no diﬀerence was seen between FC
and DOCP with regard to control of serum electrolyte
concentrations and survival time. However, the
authors reported that 14% of dogs with PH that ini-
tially were treated with FC had to be changed to
DOCP because of adverse eﬀects, poor response to
treatment, owner convenience, or ﬁnancial consider-
ations.3 In this study as well as in our study, no dog
had to be changed from DOCP to FC. Several other
authors reported that an inadequate mineralocorticoid
dosage was more commonly seen with FC than with
DOCP.4,5
In all of our dogs treated with DOCP, PRA was
completely suppressed, which in human medicine indi-
cates excessive treatment with mineralocorticoids.10
This observation is in agreement with the clinical expe-
rience of several authors that most dogs are well con-
trolled with lower doses of DOCP.3,16,17 In 1 study,
only 18.2% of dogs required the recommended dosage
of 2.2 mg/kg.3 In a recent study, no signiﬁcant diﬀer-
ences in survival time or serum electrolyte concentra-
tions were seen in dogs treated with diﬀerent dosages
of DOCP (0.4–3.8 mg/kg).17 The authors concluded
that initial DOCP dosages <2.2 mg/kg may be eﬀective
in controlling serum electrolyte concentrations in dogs
with PH without adversely aﬀecting survival.17 Our
ﬁnding of completely suppressed PRA in dogs on
DOCP further substantiates this hypothesis. We
hypothesize that it would be possible to decrease
DOCP dosage until PRA is detectable while serum
electrolytes concentrations are still normal. This would
allow calibrations of mineralocorticoid treatment. In
the dogs in which we decreased the DOCP dosage,
PRA still was completely suppressed except in 1 case.
In human medicine, 1 problem of mineralocorticoid
overdosage is the risk of iatrogenic hypertension and
potential long-term complications.17,18 In dogs treated
with 2.2 mg/kg DOCP every 30 days for 3 months,
there was no eﬀect on blood pressure.19 However, when
overdosed up to 15-fold over a period of 6 months,
dogs developed polyuria, polydipsia, decreased serum
potassium concentrations, and increased serum sodium
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concentrations.20 These ﬁndings clearly indicate the
need for additional dosing studies for the long-term
management of dogs with PH using DOCP.
In most dogs treated with FC, PRA remained
increased. The renin-angiotensin system is integral in
the maintenance of cardiovascular homeostasis.
Increased renin activity leads to enhanced production
of angiotensin I and angiotensin II. Angiotensins have
important eﬀects on vascular endothelium and vascular
smooth muscle (eg, vasoconstriction, vascular smooth
muscle cell proliferation, and atherosclerosis).21 In
humans, PRA (or more precisely angiotensin II) is a
well known cardiovascular risk factor.22–25 Strokes and
myocardial infarctions are more frequent in patients
with increased PRA. Eﬀects of increased PRA and the
enhanced growth eﬀects of angiotensin II on the car-
diovascular system and other cell systems in patients
with PH are likely and await further investigation.
In view of these observations, we prefer to start
dogs with PH on DOCP instead of FC. We follow an
approach similar to that suggested by Klein and Peter-
son and adjust the dosage individually as described
above.26
We acknowledge that measurement of PRA is not
widely available for the management of dogs with PH,
mostly because the method is not commonly available
and blood sampling as described above is not possible
for most practitioners. Measuring renin with an immu-
noassay could be considered as an alternative. The
advantage of this method is an easier sampling proce-
dure. In human medicine, renin concentrations corre-
late with PRA in healthy humans and patients with
hypertension, but not in patients with other condi-
tions.27,28 So far, no information about the correlation
of PRA and renin concentrations in dogs with diﬀerent
diseases is available. Renin concentrations in dogs
would have to be measured indirectly (ie, generation
of angiotensin in the presence of added excess angio-
tensinogen), because no speciﬁc antibody for canine
renin is commercially available.
We conclude that measurement of PRA is a promis-
ing tool for establishing dosage and monitoring miner-
alocorticoid treatment in dogs with PH. Based on our
results, DOCP treatment more eﬀectively suppresses
PRA compared to FC treatment and therefore is the
preferred mineralocorticoid treatment in dogs.
Footnotes
a Synacthen; Novartis Pharma Schweiz AG, Bern, Switzerland
(During this study 250 lg ACTH/dog were used for the ACTH
stimulation test. Today the authors use only 5 lg/kg ACTH for
the ACTH stimulation test)
b DPC Immulite 1000; Siemens Schweiz AG, Zurich, Switzerland
c Florinef; Bristol-Myers Squibb SA, 6340 Baar, Switzerland
d Percorten-V; Novartis Animal Health US, Greensboro, NC
e GraphPad Prism5; GraphPad Software, San Diego, CA
f SPSS 18.0 for Windows; SPSS Inc, Chicago, IL
Acknowledgments
The authors thank Sylvie Berthoud and Francoise
Nicoud, technical assistants at the Division of Angiol-
ogy and Hypertension, Department of Medicine, Lau-
sanne University Hospital, Switzerland for performing
the renin measurements in hours of diligent laboratory
work and colleagues at the Clinic for Small Animal
Internal Medicine, Vetsuisse Faculty University of
Zurich for contribution of cases.
Conflict of Interest Declaration: The authors disclose
no conﬂict of interest.
References
1. Javadi S, Galac S, Boer P, et al. Aldosterone-to-renin and
cortisol-to-adrenocorticotropic hormone ratios in healthy dogs
and dogs with primary hypoadrenocorticism. J Vet Intern Med
2006;20:556–561.
2. Klein SC, Peterson ME. Canine hypoadrenocorticism: Part
I. Can Vet J Rev 2010;51:63–69.
3. Kintzer PP, Peterson ME. Treatment and long-term follow-
up of 205 dogs with hypoadrenocorticism. J Vet Intern Med
1997;11:43–49.
4. Lynn RC, Feldman EC, Nelson RW. Eﬃcacy of microcrys-
talline desoxycorticosterone pivalate for treatment of hypoadre-
nocorticism in dogs. DOCP Clinical Study Group. J Am Vet
Med Assoc 1993;202:392–396.
5. Melian C, Peterson ME. Diagnosis and treatment of natu-
rally occurring hypoadrenocorticism in 42 dogs. J Small Anim
Pract 1996;37:268–275.
6. Lynn RC, Feldman EC. Treatment of canine hypoadreno-
corticism with microcrystalline desoxycorticosterone pivalate. Br
Vet J 1991;147:478–483.
7. Pascoe K. Treatment of hypoadrenocorticism in dogs. J
Am Vet Med Assoc 1993;202:1192–1193.
8. Linquette M, Lefebvre J, Fossati P, et al. Plasma renin
activity in management of Addison’s disease. Ann Endocrinol
1975;36:103–104.
9. Oelkers W, L’age M. Control of mineralocorticoid substitu-
tion in Addison’s disease by plasma renin measurement. Klin
Wochenschr 1976;54:607–612.
10. Oelkers W, Diederich S, Baehr V. Diagnosis and ther-
apy surveillance in Addison’s disease: Rapid adrenocorticotro-
pin (ACTH) test and measurement of plasma ACTH, renin
activity, and aldosterone. J Clin Endocrinol Metab 1992;75:
259–264.
11. Reisch N, Arlt W. Fine tuning for quality of life: 21st cen-
tury approach to treatment of Addison’s disease. Endocrinol
Metab Clin North Am 2009;38:407–418.
12. Baumstark ME, Sieber-Ruckstuhl NS, Mueller C, et al.
Evaluation of aldosterone concentrations in dogs with hypoadre-
nocorticism. J Vet Intern Med 2014;28:154–159.
13. Nussberger J, Fasanella d’Amore T, Porchet M, et al.
Repeated administration of the converting enzyme inhibitor cila-
zapril to normal volunteers. J Cardiovasc Pharmacol 1987;9:39–
44.
14. Juillerat L, Nussberger J, Menard J, et al. Determinants
of angiotensin II generation during converting enzyme inhibition.
Hypertension 1990;16:564–574.
15. Arlt W. The approach to the adult with newly diagnosed
adrenal insuﬃciency. J Clin Endocrinol Metab 2009;94:1059–
1067.
16. Kintzer PP, Peterson ME. Mineralocorticoid therapy of
spontaneous primary hypoadrenocorticism in 176 dogs. J Vet
Intern Med 1992;6:112.
Renin Activity in Dogs with Hypoadrenocorticism 1477
17. Bates JA, Shott S, Schall WD. Lower initial dose desoxy-
corticosterone pivalate for treatment of canine primary hypoadre-
nocorticism. Aust Vet J 2013;91:77–82.
18. Reisch N, Arlt W, Krone N. Health problems in congeni-
tal adrenal hyperplasia due to 21-hydroxylase deﬁciency. Horm
Res Paediatr 2011;76:73–85.
19. Kaplan AJ, Peterson ME. Eﬀects of desoxycorticosterone
pivalate administration on blood pressure in dogs with primary
hypoadrenocorticism. J Am Vet Med Assoc 1995;206:327–331.
20. Chow E, Campbell WR, Turnier JC, et al. Toxicity of des-
oxycorticosterone pivalate given at high dosages to clinically nor-
mal beagles for six months. Am J Vet Res 1993;54:1954–1961.
21. Osgood MJ, Harrison DG, Sexton KW, et al. Role of the
renin-angiotensin system in the pathogeneis of intimal hyperpla-
sia: Therapeutic potential for prevention of vein graft failure.
Ann Vasc Surg 2012;26:1130–1144.
22. Brunner HR, Laragh JH, Baer L, et al. Essential hyper-
tension: Renin and aldosterone, heart attack and stroke. N Engl
J Med 1972;286:441–449.
23. Brunner HR, Sealey JE, Laragh JH. Renin as a risk factor
in essential hypertension: More evidence. Am J Med
1973;55:295–302.
24. Alderman MH, Madhaven S, Ooi WL, et al. Association
of the renin-sodium proﬁle with the risk of myocardial infarction
in patients with hypertension. N Engl J Med 1991;324:1098–
1140.
25. Alderman MH, Ooi WL, Cohen H, et al. Plasma renin
activity: A risk factor for myocardial infarction in hypertensive
patients. Am J Hypertens 1997;10:1–8.
26. Klein SC, Peterson ME. Canine hypoadrenocorticism:
Part II. Can Vet J Rev 2010;51:179–184.
27. Ferrari P, Shaw SG, Nicod J, et al. Active renin versus
plasma renin activity to deﬁne aldosterone-to-renin ratio for pri-
mary aldosteronism. J Hypertens 2004;22:377–381.
28. Campbell DJ, Nussberger J, Stowasser M, et al. Activity
assays and immunoassays for plasma Renin and prorenin: Infor-
mation provided and precautions necessary for accurate measure-
ment. Clin Chem 2009;55:867–877.
1478 Baumstark et al
